(S (S (NP (NP (JJ Uncompetitive) (NNS antagonists)) (PP (IN of) (NP (DT the) (NML (NN N) (HYPH -) (NN methyl)) (NML (NN D) (HYPH -) (NN aspartate)) (NN receptor) (PRN (-LRB- -LRB-) (NP (NN NMDAR)) (-RRB- -RRB-))))) (VP (VBP have) (VP (VBN demonstrated) (NP (JJ therapeutic) (NN benefit)) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NP (JJ neurological) (NNS diseases)) (PP (JJ such) (IN as) (NP (NP (NNP Parkinson) (POS 's)) (CC and) (NP (NNP Alzheimer) (POS 's))))))))))) (, ,) (CC but) (S (NP (DT some)) (ADVP (RB also)) (VP (VBP cause) (NP (NP (JJ dissociative) (NNS effects)) (SBAR (WHNP (WDT that)) (S (VP (VBP have) (VP (VBN led) (PP (IN to) (NP (NP (DT the) (NN synthesis)) (PP (IN of) (NP (JJ illicit) (NNS drugs)))))))))))) (. .))
(S (NP (DT The) (NN ability) (S (VP (TO to) (VP (VB generate) (NP (NP (NN NMDAR) (NNS antagonists)) (ADJP (FW in) (FW silico))))))) (VP (VBZ is) (ADVP (RB therefore)) (ADJP (JJ desirable)) (PP (CC both) (PP (IN for) (NP (JJ new) (NN medication) (NN development))) (CC and) (PP (IN for) (S (VP (VBG preempting) (CC and) (VBG identifying) (NP (JJ new) (NN designer) (NNS drugs))))))) (. .))
(S (ADVP (RB Recently)) (, ,) (NP (JJ generative) (NML (JJ deep) (NN learning)) (NNS models)) (VP (VBP have) (VP (VBN been) (VP (VBN applied) (PP (IN to) (NP (NP (ADJP (FW de) (FW novo)) (NN drug) (NN design)) (PP (IN as) (NP (DT a) (NN means))))) (S (VP (TO to) (VP (VB expand) (NP (NP (DT the) (NN amount)) (PP (IN of) (NP (NP (JJ chemical) (NN space)) (SBAR (WHNP (WDT that)) (S (VP (MD can) (VP (VB be) (VP (VBN explored) (PP (IN for) (NP (JJ potential) (ADJP (NN drug) (HYPH -) (JJ like)) (NNS compounds))))))))))))))))) (. .))
(S (PP (IN In) (NP (DT this) (NN study))) (, ,) (NP (PRP we)) (VP (VBP assess) (NP (NP (DT the) (NN application)) (PP (IN of) (NP (DT a) (JJ generative) (NN model)))) (PP (IN to) (NP (NP (DT the) (NN NMDAR) (S (VP (TO to) (VP (VB achieve) (NP (CD two) (JJ primary) (NNS objectives)))))) (: :) (NP (LST (-LRB- -LRB-) (LS i) (-RRB- -RRB-)) (NP (NP (DT the) (NN creation) (CC and) (NN release)) (PP (IN of) (NP (NP (DT a) (JJ comprehensive) (NN library)) (PP (IN of) (NP (ADJP (RB experimentally) (VBN validated)) (NML (NNP NMDAR) (NML (NN phencyclidine) (-LRB- -LRB-) (NN PCP) (-RRB- -RRB-)) (NN site)) (NNS antagonists)))))) (S (VP (TO to) (VP (VB assist) (NP (DT the) (NN drug) (NN discovery) (NN community)))))) (CC and) (NP (LST (-LRB- -LRB-) (LS ii) (-RRB- -RRB-)) (NP (DT an) (NN analysis)) (PP (IN of) (NP (CC both) (NP (NP (DT the) (NNS advantages)) (VP (VBN conferred) (PP (IN by) (S (VP (VBG applying) (NP (JJ such) (JJ generative) (NML (JJ artificial) (NN intelligence)) (NNS models)) (PP (IN to) (NP (NN drug) (NN design)))))))) (CC and) (NP (NP (DT the) (JJ current) (NNS limitations)) (PP (IN of) (NP (DT the) (NN approach)))))))))) (. .))
(S (S (NP (PRP We)) (VP (VBP apply))) (, ,) (CC and) (S (VP (VB provide) (NP (NN source) (NN code)) (PP (IN for)) (, ,) (NP (NP (DT a) (NN variety)) (PP (IN of) (NP (NP (ADJP (NP (NN ligand) (HYPH -) (CC and) (NN structure)) (HYPH -) (VBN based)) (NN assessment) (NNS techniques)) (VP (VBN used) (PP (IN in) (NP (JJ standard) (NN drug) (NN discovery) (NNS analyses))) (PP (IN to) (NP (DT the) (JJ deep) (ADJP (NN learning) (HYPH -) (VBN generated)) (NNS compounds))))))))) (. .))
(S (NP (PRP We)) (VP (VBP present) (S (NP (NP (CD twelve) (NN candidate) (NNS antagonists)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (RB not) (ADJP (JJ available) (PP (IN in) (NP (VBG existing) (NN chemical) (NNS databases)))))))) (VP (TO to) (VP (VB provide) (NP (NP (DT an) (NN example)) (PP (IN of) (SBAR (WHNP (WP what)) (S (NP (NP (DT this) (NN type)) (PP (IN of) (NP (NN workflow)))) (VP (MD can) (VP (VB achieve)))))))))) (, ,) (SBAR (IN though) (S (NP (NP (NN synthesis)) (CC and) (NP (NP (JJ experimental) (NN validation)) (PP (IN of) (NP (DT these) (NNS compounds))))) (VP (VBZ is) (ADVP (RB still)) (VP (VBN required)))))) (. .))
